Protalix BioTherapeutics (PLX) EPS (Basic) Growth (3y) (2013 - 2026)
Powered by 
Analysis
Protalix BioTherapeutics (PLX) EPS (Basic) Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.74 Bn | 192.75 Bn | 7.24 Bn | 19.50% |
| 2 | Gilead Sciences | 179.96 Bn | 176.78 Bn | 6.22 Bn | -129.90% |
| 3 | Vertex Pharmaceuticals | 131.20 Bn | 123.35 Bn | 2.84 Bn | 6.85% |
| 4 | Regeneron Pharmaceuticals | 82.05 Bn | 74.05 Bn | 3.93 Bn | 11.71% |
| 5 | Argenx Se | 60.28 Bn | 55.10 Bn | 1.37 Bn | 86.03% |
| 6 | Moderna | 53.67 Bn | 48.54 Bn | 52.00 Mn | 18.44% |
| 7 | Alnylam Pharmaceuticals | 33.08 Bn | 29.78 Bn | 992.69 Mn | 36.73% |
| 8 | Biogen | 31.91 Bn | 30.62 Bn | 1.96 Bn | -45.60% |
| 9 | Roivant Sciences | 29.22 Bn | 29.22 Bn | 1.16 Mn | - |
| 10 | Protalix BioTherapeutics | 217.96 Mn | 177.31 Mn | 12.13 Mn | -41.95% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -41.95% |
| Mar 31, 2026 | 83.82% |
| Dec 31, 2025 | 13.81% |
| Sep 30, 2025 | 34.30% |
| Jun 30, 2025 | 26.38% |
| Mar 31, 2025 | 1.79% |
| Dec 31, 2024 | 44.48% |
| Sep 30, 2024 | 35.12% |
| Jun 30, 2024 | 50.66% |
| Mar 31, 2024 | 24.60% |
| Dec 31, 2023 | 11.35% |
| Sep 30, 2023 | 43.03% |
| Jun 30, 2023 | 57.00% |
| Mar 31, 2023 | -38.33% |
| Dec 31, 2022 | -121.40% |
| Sep 30, 2022 | 33.24% |
| Jun 30, 2022 | 40.01% |
| Mar 31, 2022 | 53.70% |
| Dec 31, 2021 | 26.41% |
| Sep 30, 2021 | 36.87% |